Literature DB >> 14711014

Stem cells: a promising source of pancreatic islets for transplantation in type 1 diabetes.

Cale N Street1, Ray V Rajotte, Gregory S Korbutt.   

Abstract

Diabetes is a disease that affects millions and causes a major burden on the health care system. Type 1 diabetes has traditionally been managed with exogenous insulin therapy, however factors such as cost, lifestyle restriction, and life threatening complications necessitate the development of a more efficient treatment alternative. Pancreas transplantation, and more recently transplant of purified pancreatic islets, has offered the potential for independence from insulin injections. Islet transplantation is gaining acceptance as it has been shown to be effective for certain patients with type 1 diabetes. One obstacle, however, is the fact that there is an inadequate supply of cadaveric human islets to implement this procedure on a widespread clinical basis. A promising source of transplantable islets in the future will come through the use of adult or embryonic stem cells. This chapter presents an overview of the advancements made in the development of a stem cell based application to islet transplantation. Advantages and limitations are discussed regarding the use of embryonic stem cells, adult pancreatic stem/progenitor cells, and the use of nonpancreatic tissues based on current experimental models in the literature. It is concluded that stem cells offer the greatest potential for the development of an abundant source of pancreatic islets, although specific obstacles must be overcome before this can become a reality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711014     DOI: 10.1016/s0070-2153(03)58004-8

Source DB:  PubMed          Journal:  Curr Top Dev Biol        ISSN: 0070-2153            Impact factor:   4.897


  4 in total

1.  Differentiation of dermis-derived multipotent cells into insulin-producing pancreatic cells in vitro.

Authors:  Chun-Meng Shi; Tian-Min Cheng
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

2.  Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

Authors:  Andreas K Nussler; Katrin Zeilinger; Lilianna Schyschka; Sabrina Ehnert; Jörg C Gerlach; Xueying Yan; Serene M L Lee; Maren Ilowski; Wolfgang E Thasler; Thomas S Weiss
Journal:  J Mater Sci Mater Med       Date:  2011-04-03       Impact factor: 3.896

3.  Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin.

Authors:  L Denner; Y Bodenburg; J G Zhao; M Howe; J Cappo; R G Tilton; J A Copland; N Forraz; C McGuckin; R Urban
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

Review 4.  Biomaterials as carrier, barrier and reactor for cell-based regenerative medicine.

Authors:  Chunxiao Qi; Xiaojun Yan; Chenyu Huang; Alexander Melerzanov; Yanan Du
Journal:  Protein Cell       Date:  2015-06-19       Impact factor: 14.870

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.